Wei C Chen

7435830, Oct 14, 2008

Mar 2, 2005

11/071880

Andrew M. K. Pennell - San Francisco CA, US
James B. Aggen - Burlingame CA, US
J. J. Kim Wright - Redwood City CA, US
Subhabrata Sen - Bangalore Karnataka, IN
Wei Chen - Fremont CA, US
Daniel Joseph Dairaghi - Palo Alto CA, US
Penglie Zhang - Foster City CA, US

ChemoCentryx, Inc. - Mountain View CA

C07D 487/04

548453

Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.

7435831, Oct 14, 2008

Sep 1, 2005

11/219637

Wei Chen - Fremont CA, US
Penglie Zhang - Foster City CA, US
James B. Aggen - Burlingame CA, US
Daniel Joseph Dairaghi - Palo Alto CA, US
Andrew M. K. Pennell - San Francisco CA, US
Subhabrata Sen - Bangalore Karnataka, IN
J. J. Kim Wright - Redwood City CA, US

ChemoCentryx, Inc. - Mountain View CA

C07D 487/04

548453

Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.

7486851, Feb 3, 2009

Apr 27, 2005

11/115531

Di Yang - Fremont CA, US
Giovanni Barbarossa - Saratoga CA, US
Wei Chen - Fremont CA, US

Avanex Corporation - Fremont CA

G02B 6/00

385 27

One embodiment of the present invention includes a plurality of first optical elements and a second optical element optically coupled to one another in cascaded fashion. Each first optical element has a group delay response characterized by a first period such that only one group delay peak occurs within a first channel. By contrast, the second optical element has a group delay response characterized by a second period, which is less than the first period, such that more than one group delay peak occurs within the first channel. The preferred embodiment uses cascaded GT etalons to provide the desired group delay responses. One advantage of the present invention is that the passband of the dispersion compensator is increased relative to prior art designs without increasing insertion losses. Alternatively, the same passband common in prior art designs may be achieved with fewer GT etalons, thereby reducing insertion losses.

7524845, Apr 28, 2009

Jun 22, 2006

11/474132

Penglie Zhang - Foster City CA, US
Andrew M. K. Pennell - San Francisco CA, US
John J. Kim Wright - Redwood City CA, US
Wei Chen - Fremont CA, US
Manmohan R. Leleti - Sunnyvale CA, US
Yandong Li - San Jose CA, US
Lianfa Li - Palo Alto CA, US
Yuan Xu - Fremont CA, US

ChemoCentryx, Inc. - Mountain View CA

A61K 31/5377
A61K 31/496
C07D 471/04
C07D 487/04

5142358, 51425304, 514248, 514249, 5142621, 544121, 544362, 544236, 544262, 544350

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

7576106, Aug 18, 2009

Oct 11, 2006

11/580202

Penglie Zhang - Foster City CA, US
Andrew M. K. Pennell - San Francisco CA, US
Wei Chen - Fremont CA, US
Kevin Lloyd Greenman - Burlingame CA, US
Edward J. Sullivan - San Jose CA, US
Lianfa Li - Palo Alto CA, US

ChemoCentryx, Inc. - Mountain View CA

C07D 401/06
A61K 31/454

514326, 546211

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

7576218, Aug 18, 2009

Oct 11, 2006

11/546938

Penglie Zhang - Foster City CA, US
Andrew M. K. Pennell - San Francisco CA, US
Wei Chen - Fremont CA, US
Kevin Lloyd Greenman - Burlingame CA, US
Lianfa Li - Palo Alto CA, US
Edward J. Sullivan - San Jose CA, US
Valeri V. Martichonok - San Francisco CA, US

ChemoCentryx, Inc. - Mountain View CA

C07D 401/06
A61K 31/454

546211, 514326

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

7589199, Sep 15, 2009

Dec 8, 2004

11/008774

Andrew M. K. Pennell - San Francisco CA, US
James B. Aggen - Burlingame CA, US
J. J. Kim Wright - Redwood City CA, US
Subhabrata Sen - Sunnyvale CA, US
Brian E. McMaster - Mountain View CA, US
Daniel Joseph Dairaghi - Palo Alto CA, US
Wei Chen - Fremont CA, US
Penglie Zhang - Foster City CA, US

ChemoCentryx, Inc. - Mountain View CA

A61K 31/496
C07D 401/14
C07D 403/14

544295, 544364, 51425219, 51425309

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

7718662, May 18, 2010

Oct 16, 2009

12/581044

Wei Chen - Fremont CA, US
David J. Loury - San Jose CA, US
Tarak D. Mody - Sunnyvale CA, US

Pharmacyclics, Inc. - Sunnyvale CA

C07D 487/04
A61K 31/519
A61P 37/06
A61P 17/06
A61P 11/06
A61P 35/02
A61P 35/04

5142621, 544262

Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.